Q4 EPS Estimate for Zevra Therapeutics Boosted by Analyst

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at Roth Capital upped their Q4 2025 EPS estimates for shares of Zevra Therapeutics in a report released on Wednesday, November 5th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of $0.06 for the quarter, up from their prior forecast of ($0.01). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics’ FY2026 earnings at $0.64 EPS, FY2027 earnings at $1.49 EPS, FY2028 earnings at $1.90 EPS and FY2029 earnings at $2.11 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.03. The company had revenue of $26.06 million during the quarter, compared to the consensus estimate of $26.64 million. Zevra Therapeutics had a net margin of 4.33% and a negative return on equity of 112.40%.

Other research analysts have also issued research reports about the company. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday. Zacks Research downgraded shares of Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Tuesday, October 14th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.80.

Zevra Therapeutics Stock Down 3.1%

Zevra Therapeutics stock opened at $8.81 on Monday. Zevra Therapeutics has a fifty-two week low of $6.19 and a fifty-two week high of $13.16. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85. The company has a market capitalization of $495.99 million, a P/E ratio of -41.95 and a beta of 1.52. The stock has a 50-day simple moving average of $9.56 and a 200-day simple moving average of $9.58.

Insider Activity

In other Zevra Therapeutics news, Director John B. Bode bought 5,000 shares of the company’s stock in a transaction on Tuesday, August 19th. The shares were bought at an average price of $9.16 per share, for a total transaction of $45,800.00. Following the transaction, the director owned 45,000 shares of the company’s stock, valued at approximately $412,200. This trade represents a 12.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Neil F. Mcfarlane sold 19,500 shares of the stock in a transaction on Friday, October 10th. The stock was sold at an average price of $10.82, for a total value of $210,990.00. Following the completion of the transaction, the chief executive officer owned 222,016 shares of the company’s stock, valued at $2,402,213.12. The trade was a 8.07% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Woodline Partners LP raised its position in Zevra Therapeutics by 11.5% during the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock worth $34,571,000 after acquiring an additional 476,032 shares during the last quarter. Readystate Asset Management LP grew its position in shares of Zevra Therapeutics by 924.6% in the first quarter. Readystate Asset Management LP now owns 683,032 shares of the company’s stock valued at $5,116,000 after purchasing an additional 616,370 shares during the last quarter. Retirement Planning Co of New England Inc. increased its stake in shares of Zevra Therapeutics by 6.9% during the 1st quarter. Retirement Planning Co of New England Inc. now owns 550,180 shares of the company’s stock worth $4,121,000 after purchasing an additional 35,348 shares in the last quarter. Velan Capital Investment Management LP raised its position in shares of Zevra Therapeutics by 121.7% during the 1st quarter. Velan Capital Investment Management LP now owns 665,000 shares of the company’s stock worth $4,981,000 after purchasing an additional 365,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Zevra Therapeutics by 2.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company’s stock worth $1,148,000 after purchasing an additional 3,827 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.